Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
¥ 24
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
OncoTherapy Science, Inc. researches and develops anti-cancer medicines and therapies in Japan. Its clinical development product pipeline includes small-molecule drugs, such as OTS167, a maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.
Data is available to registered users only
Buy
Sell